Bilcare Ltd Stock Analysis

BSE: 526853 | NSE: | Plastic Products | Small Cap

BSE Share Price 02-Dec-2022 18:01
37.50 -0.10 (-0.27%)

DeciZen - Make an Informed Decision on Bilcare

M-Cap below 100cr DeciZen not available

Bilcare Price Chart

P/E Ratio (SA) :
Market Cap :
88.3 Cr.
52-wk low :
52-wk high :
Bole Toh?

1. Is Bilcare Ltd a good quality company?

Data is not available for this company.

2. Is Bilcare Ltd undervalued or overvalued?

The key valuation ratios of Bilcare Ltd's currently when compared to its past seem to suggest it is in the Fair zone.

3. Is Bilcare Ltd a good buy now?

The Price Trend analysis by MoneyWorks4Me indicates it is Weak which suggest that the price of Bilcare Ltd is likely to Fall in the short term. However, please check the rating on Quality and Valuation before investing.

10 Year X-Ray of Bilcare:

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.

Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.

Value Creation

Value Creation Index Colour Code Guide

ROCE % 5.8%-2%-4.7%-2.8%-5.4%-15.2%-22.3%-7.7%3.9%0.3%-
Value Creation Index -0.6-1.1-1.3-1.2-1.4-2.1-2.6-1.6-0.7-1.0-

Growth Parameters

Growth Parameters Colour Code Guide

Sales 727401331315286258240212304430520
YoY Gr. Rt. %--44.8%-17.5%-4.8%-9.5%-9.8%-6.9%-11.7%43.6%41.3%-
Adj EPS 18.4-62.5-78.2-29.7-49-106.7-133.3-50-9.8-19.5-14.7
BVPS (₹) 411.1363283.3264.4236.3202.468.625.125.818.412.9
Adj Net Profit 43.3-147-184-69.8-115-251-314-118-23.1-45.8-35
Cash Flow from Ops. 144177-16.728.437.
Debt/CF from Ops. 9.66.9-6934.324.1119.41410-1642.714.9-


CAGR Colour Code Guide

9 Years 5 Years 3 Years 1 Years
Sales -5.7%8.5%21.5%41.3%
Adj EPS -200.6%NANANA
BVPS -29.2-40-35.5-28.5
Share Price -16.3% -11.3% 25.4% -51.5%

Key Financial Parameters

Performance Ratio Colour Code Guide

Return on Equity % 4.5-16.1-24.2-10.8-19.6-48.6-98.4-106.7-38.6-88-93.8
Op. Profit Mgn % 25.2166.48.6-10.40.8-
Net Profit Mgn % 6-36.6-55.6-22.1-40.4-97.5-130.9-55.6-7.6-10.7-6.7
Debt to Equity
Working Cap Days 282477592448278290300346273229127
Cash Conv. Cycle 1491612121406164533640520

Recent Performance Summary

Sales growth is growing at healthy rate in last 3 years 21.47%

Sales growth is good in last 4 quarters at 47.21%

Return on Equity is Poor

Debt to equity has increased versus last 3 years average to 15.89

Latest Financials - Bilcare Ltd.

Standalone Consolidated
TTM EPS (₹) -14.7 -13.6
TTM Sales (₹ Cr.) 520 966
BVPS (₹.) 12.9 27.3
Reserves (₹ Cr.) 7 41
P/BV 2.91 1.40
PE 0.00 0.00
From the Market
52 Week Low / High (₹) 34.40 / 114.35
All Time Low / High (₹) 5.00 / 1830.00
Market Cap (₹ Cr.) 88.3
Equity (₹ Cr.) 23.6
Face Value (₹) 10
Industry PE 20.6

Management X-Ray of Bilcare :

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged *1.391.391.391.391.391.391.391.391.391.39
* Pledged shares as % of Promoter's holding (%)

Event Update

Login/Register to view analysis.

Analyst's Notes

Key Ratios of Bilcare

Adj EPS (Rs.)
Sales (Cr.)
ROE (%)
ROCE (%)


Bilcare Ltd FAQs

Company share prices are keep on changing according to the market conditions. The closing price of Bilcare on 02-Dec-2022 18:01 is : 37.50.
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 02-Dec-2022 18:01 the market cap of Bilcare stood at ₹ 88.29.
The latest PE ratio of Bilcare as of 02-Dec-2022 18:01 is 0.00.
The latest PB ratio of Bilcare as of 02-Dec-2022 18:01 is 2.91
The 52-week high of Bilcare is ₹ 114.3 and the 52-week low is ₹ 34.40.
The TTM revenue is Trailing Twelve Months sales. The TTM revenue / sales of Bilcare is ₹ 520.1 ( Cr.) .

About Bilcare Ltd

Bilcare, incorporated in the year 1987, is engaged in manufacturing pharmaceutical packaging. It has an experience of working with 500 pharma manufacturing companies worldwide.Bilcare is a global leader and an innovation-led packaging solutions provider that partners with the pharmaceutical industry to improve patient healthcare outcomes. The company endeavor to deliver effective and affordable solutions that enhance the speed and quality of drug discovery and help build and protect brands by ensuring the delivery of genuine medicines to patients.

Bilcare PPI offers Innovative Pharmaceutical Packaging Solutions comprising of a wide range of specialty Polymer Films and Aluminum Foils mainly used for packaging of solid dosage pharmaceutical products.

Bilcare GCS provides Global Clinical Material Supplies for new drug discovery projects.

Bilcare Technologies provides Anti-counterfeit (ncID - nonclonableID) solutions for product & people ID authentication and security
The company develops design keeping various aspects into consideration such as end-user, optimum material, composite dosages, on-pack communication, cost-effective, regulatory requirements, etc.It also offers pharmaceutical research and clinical services.

It has representative offices located in Argentina, Bangladesh, Chile, Colombia, Czech Republic, Egypt, France, Indonesia, Iran, Israel, Italy, Jordan, South Korea, Malaysia, Mexico, Pakistan, Saudi Arabia, South Africa, Spain, Taiwan, Thailand, Turkey, Venezuela and Vietnam.

It maintains quality standards prescribed by various agency such USFDA, DEA, IQA, SAP, ISO 9001 and 14001.Bilcare has a global customer base and customers comprise many of the largest global pharmaceutical companies viz. Bristol-Myers Squibb, Dr. Reddy’s, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, Ranbaxy, Sanofi-Aventis, Teva to name a few. Bilcare has a strong customer base of over 2,500 customers in over 50 countries worldwide.

For packaging purposes the company uses material like blister films range, aluminium foils, cold formed blisters, wrap systems, closures & containers, flexibles and eco-friendly paper composites.

Bilcare Singapore Pte a wholly owned subsidiary acquired 100 percent stakes in Singapore-based Singular ID. The firm specialises in technology to identify fake drugs.

In 2010 Bilcare won Pharmexcil / Govt of India Patent Award-2009-10.

Read More Read Less
You have 2 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login | Register Now